MegaNatural-BP Claims Get Mixed Review from NAD
October 15, 2008
NEW YORK—The National Advertising Division (NAD) of the Council of Better Business Bureaus issued a statement that it determined Polyphenolics has reasonable support for certain claims it has made about its MegaNatural-BP product, but recommended the company discontinue other claims.
NAD examined advertising for MegaNatural-BP and requested substantiation for certain claims including:
“Provide relief with half the cost, half the dose and half the time”
“MegaNatural-BP was evaluated in two human clinical trials. In the first clinical on patients with metabolic syndrome, their systolic blood pressure dropped by 12 mm and diastolic blood pressure dropped an average of 8 mm when taking a minimum of 150 mg once per day for one month.”
“In the second study on participants with prehypertension, their systolic blood pressure dropped 8 mm and diastolic dropped 5 mm when taking 300 mg once per day for 2 months.”
“MegaNatural-BP is self affirmed GRAS for beverages and most food products.”
“MegaNatural-BP could be the ideal ingredient for your new condition-specific supplement or your new functional food or beverage.”
Following its review of the evidence provided by the advertiser, including the results of two clinical trials, NAD determined Polyphenolics provided a reasonable basis for performance claims that detailed results of the clinical studies. It also found reasonable support for the GRAS statement, and that the “ideal ingredient” statement is clearly the company’s opinion, not a claim.
However, NAD recommended the company discontinue the claim regarding “half the cost, half the dose and half the time,” although NAD did state Polyphenolics could continue discussing differences between MegaNatural-BP and competing antigen converting enzyme inhibitors. NAD further suggested any claims include recommendations that consumers use the product as part of a lifestyle management program and consult with a health care provider before taking the product.
In an advertiser’s statement, the company said it “understands NAD’s decision as written and appreciates your thorough and well-explained rationale. Polyphenolics agrees to modify its advertising as recommended.”
You May Also Like